Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer

Lisa A Cannon-Albright, Shamus R Carr, Wallace Akerley, Lisa A Cannon-Albright, Shamus R Carr, Wallace Akerley

Abstract

Introduction: Published risk estimates for diagnosis of lung cancer based on family history are typically focused on close relatives, rather than a more diverse or complete family history. This study provides estimates of relative risk (RR) for lung cancer based on comprehensive family history data obtained from a statewide cancer registry linked to a high-quality genealogy data resource that is extensive and deep. The risk estimates presented avoid common recall, recruitment, ascertainment biases, and are based on an individual's (proband's) lung cancer family history constellation (pattern of lung cancer affected relatives); numerous constellations are explored.

Methods: We used a population-based genealogic resource linked to a statewide electronic Surveillance Epidemiology and End Results program cancer registry to estimate RR for lung cancer for an individual based on their lung cancer family history. The family history data available for a proband included degree of relationship (first- to third-degree), paternal or maternal family lung cancer history, number of lung cancer-affected relatives, and age at diagnosis of affected relatives. More than 1.3 million probands with specific constellations of lung cancer were analyzed. To estimate RRs for lung cancer, the observed number of lung cancer cases among probands with a specific family history constellation was compared to the expected number using internal cohort-specific rates.

Results: A total of 5048 lung cancer cases were identified. Significantly elevated RR was observed for any number of lung cancer-affected relatives among first-, second-, or third-degree relatives. RRs for lung cancer were significantly elevated for each additional lung cancer first-degree relative (FDR) ranging from RR = 2.57 (confidence interval [CI] 95%: 2.39, 2.76) for 1 or more FDR to RR = 4.24 (CI 95%: 1.56, 9.23) for 3 or more FDRs affected. In an absence of FDR family history, increased risk for lung cancer was significant for increasing numbers of affected second-degree relatives (SDRs) ranging from 1.41 (CI 95%: 1.30, 1.52) for 1 or more SDRs to 4.76 (CI 95%: 1.55, 11.11) for 4 or more SDRs. In the absence of affected FDRs and SDRs, there were significantly increased risks based on lung cancer-affected third-degree relatives (TDRs) ranging from 1.18 (CI 95%: 1.11, 1.24) for 1 or more affected TDRs to 1.55 (CI 95%: 1.03, 2.24) for 4 or more affected TDRs. RRs were significantly increased with earlier age at diagnosis of a FDR, and equivalent risks for maternal compared to paternal history were observed.

Conclusions: This study provides population-based estimates of lung cancer risk based on a proband's complete family history (lung cancer constellation). Many individuals at two to five or more times increased risk for lung cancer are identified. Estimates of RR for lung cancer based on family history are arguably relevant clinically. The constellation RR estimates presented could serve in individual decision-making to direct resource use for lung cancer screening, and could be pivotal in decision-making for screening, treatment, and post-treatment surveillance.

Keywords: Family history; Genetic epidemiology; Hereditary factors; Lung cancer.

Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

References

    1. Skolnick MH & Cannon-Albright LA Genetic predisposition to breast cancer. Cancer 70, 1747–1754 (1992).
    1. Albright F, Teerlink C, Werner TL & Cannon Albright LA Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer 12, 138 (2012).
    1. Hemminki K, Sundquist J & Brandt A Familial mortality and familial incidence in cancer. Journal of Clinical Oncology 29, 712–718 (2011).
    1. Amundadottir LT et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 1, e65 (2004).
    1. Carr SR, Akerley W, Hashibe M & Cannon Albright LA Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax 70, 1033–1039 (2015).
    1. Nitadori J-I et al. Association between lung cancer incidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC study. Chest 130, 968–975 (2006).
    1. Jonsson S et al. Familial risk of lung carcinoma in the Icelandic population. JAMA 292, 2977–2983 (2004).
    1. Cannon L, Bishop DT, Skolnick M, Hunt S & Lyon JL Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1, 47–69 (1982).
    1. Cannon-Albright LA et al. Familiality of cancer in Utah. Cancer Res. 54, 2378–2385 (1994).
    1. Teerlink CC, Albright FS, Lins L & Cannon Albright LA A comprehensive survey of cancer risks in extended families. Genet. Med 14, 107–114 (2012).
    1. Samet JM et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin. Cancer Res 15, 5626–5645 (2009).
    1. Jin Y, Xu Y, Xu M & Xue S Increased risk of cancer among relatives of patients with lung cancer in China. BMC Cancer 5, 146 (2005).
    1. Turner MC et al. Radon and lung cancer in the American Cancer Society cohort. Cancer Epidemiol. Biomarkers Prev 20, 438–448 (2011).
    1. Coté ML et al. Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur. J. Cancer 48, 1957–1968 (2012).
    1. Carr SR, Akerley W & Cannon Albright LA Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. J Thorac Oncol 13, 938–945 (2018).
    1. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE & Rothschild H Increased familial risk for lung cancer. J. Natl. Cancer Inst. 76, 217–222 (1986).
    1. National Lung Screening Trial Research Team et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365, 395–409 (2011).
    1. Wender R et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 63, 107–117 (2013).

Source: PubMed

3
구독하다